Centers for Disease Control and Prevention, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341–4146, Telephone number 770–488–2717, e-mail address: *wfr4@cdc.gov.*

For program technical assistance, contact: Emily Koumans, MD, Division of STD Prevention, Centers for Disease Control and Prevention, NCHSTP/DSTD, 10 Corporate Square Blvd, Atlanta, GA 30329, Telephone number 404–639–8870, e-mail address: *svs5@cdc.gov.*

Dated: August 13, 2002.

**Sandra R. Manning,**

*Director, Procurement and Grants Office, Centers for Disease Control and Prevention.*

[FR Doc. 02–21080 Filed 8–19–02; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### A Public Health Action Plan To Combat Antimicrobial Resistance (Part II: Global Issues): Meeting for Public Comment on Development of Part II of the Action Plan (Global Issues)

The Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institutes of Health (NIH) announce an open meeting concerning antimicrobial resistance.

*Name:* A Public Health Action Plan To Combat Antimicrobial Resistance (Part II: Global Issues): Meeting for Public Comment on the Development of Part II of the Action Plan (Global Issues).

*Time and Date:* 8:30 a.m.–3:30 p.m., September 26, 2002.

*Place:* Manchester Grand Hyatt, Manchester Ballroom A & B, 8120 One Market Place, San Diego, California, 92101, U.S.A. Tel: 619–232–1234; Fax: 619–232–5678.

*Status:* Open to the public, interested experts who are citizens of the United States or other countries are welcomed and encouraged to attend. Limited only by the space available.

*Purpose:* To solicit comments to aid in the development of A Public Health Action Plan to Combat Antimicrobial Resistance (Part II: Global Issues). The Action Plan serves as a blueprint for specific actions of U.S. government agencies to address the global problem of antimicrobial resistance.

*Matters to be Discussed:* The agenda will consist of welcome and introductory comments, focusing on the three areas that comprise Part II of the Action Plan, lasting about 90 minutes. The three focus areas are: Surveillance, Prevention and Control, and Research. Breakout groups will then meet to discuss each focus area for approximately 3 hours. Following lunch, the entire group will reconvene for a concluding plenary session lasting approximately 2 hours.

Comments and suggestions from the public for Federal agencies related to each of the focus areas will be taken under advisement by the Antimicrobial Resistance Interagency Task Force. The agenda does not include development of consensus positions, guidelines, or discussions or endorsement of specific commercial products.

The Action Plan (Part I: Domestic Issues) is available at *http://www.cdc.gov/drugresistance.* The public meeting is sponsored by the CDC, FDA, and NIH in collaboration with eight other Federal agencies and departments involved in developing and writing A Public Health Action Plan to Combat Antimicrobial Resistance (Part II: Global Issues).

Agenda items are subject to change as priorities dictate.

Limited time will be available for oral questions, comments, and suggestions from the public. Depending on the number wishing to comment, a time limit may be imposed. In the interest of time, visual aids will not be permitted, although written material may be submitted for subsequent review by the Task Force. Written comments and suggestions from the public are encouraged and should be received by the contact person or email listed below prior to the opening of the meeting or no later than the end of October 2002.

Persons who anticipate attending the meeting are requested to send written notification to the contact person below by September 23, 2002, including name, organization (if applicable), address, phone, fax, and email address.

*Contact Person for More Information:* Ms. Vickie Garrett, Antimicrobial Resistance, Office of the Director, NCID, CDC, Mailstop C–12, 1600 Clifton Road, NE., Atlanta, GA 30333; telephone 404–639–2603; fax 404–639–4197; or e-mail *aractionplan@cdc.gov*.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 14, 2002.

**Joseph E. Salter,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 02–21083 Filed 8–19–02; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### Clinical Laboratory Improvement Advisory Committee (CLIAC): Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Clinical Laboratory Improvement Advisory Committee (CLIAC).

*Times and Dates:*

8:30 a.m.–5:00 p.m., September 11, 2002.
8:30 a.m.–3:30 p.m., September 12, 2002.

*Place:* CDC, Koger Center, Williams Building, Conference Rooms 1802 and 1805, 2877 Brandywine Road, Atlanta, Georgia 30341.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

*Purpose:* This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact on medical and laboratory practice of proposed revisions to the standards; and the modification of the standards to accommodate technological advances.

*Matters To Be Discussed:* The agenda will include updates from CDC, the Food and Drug Administration, and the Centers for Medicare & Medicaid Services; a report on the Coordinating Council for Clinical Laboratory Workforce's April 2002 meeting and subsequent activities; reports from several organizations on healthcare workforce issues; Department of Health and Human Services' bioterrorism preparedness and response activities; a report on the Secretary's Advisory Committee on Genetic Testing May 2002 meeting; genetics testing survey results from the Pacific Northwest Sentinel Network; and an update on plans for the April 2003 Quality Institute.

Agenda items are subject to change as priorities dictate.

*Contact Person for Additional Information:* Rhonda Whalen, Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, Mailstop F–11, Atlanta, Georgia 30341–3724, telephone 770/488–8042, fax 770/488–8279.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 14, 2002.

**Joseph E. Salter,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 02–21081 Filed 8–19–02; 8:45 am]

**BILLING CODE 4163–18–P**